Part of the Law Commons
The Cost of Evidence: Examining the FDA's Treatment of Critically-Needed Drugs from an Ex Ante Perspective, Julie Dorais J.D., M.P.H. North Carolina Central University Science & Intellectual Property Law Review
PDF
Advanced Search
